KRASmutations in combination with primary tumor size are not associated with a worse prognosis in early Non-Small Cell Lung Cancer

Abstract

AbstractPurposeThe aim of this study it to investigate the combined impact ofKRASmutational status and tumor size on overall survival and risk of death in stage I and II NSCLC.MethodsAll consecutive patients molecularly assessed and diagnosed between 2016-2018 with stage I-II NSCLC in the region of West Sweden were included in this multi-center retrospective study. Primary study outcome was overall survival (OS) and risk of death (HR).ResultsOut of 310 Stage I-II NSCLC patients, 37% harbored an activating mutation in theKRASgene (KRASMUT). Our study confirmed staging and tumor size as prognostic factors.KRASmutational status was not found to impact overall survival and no difference in risk of death was observed when combiningKRASmutational status and primary tumor size.ConclusionsKRASmutations in combination with primary tumor size are not associated with a worse prognosis in stage I and II NSCLC.Simple SummaryIn this retrospective study including 310 patients with early (Stage I-II) non-small cell lung cancer (NSCLC), we investigated weatherKRASmutational status in combination with primary tumor size at diagnosis had any impact on clinical outcome. First, we analysed overall survival of patients grouped based on absence (KRASWT) or presence (KRASMUT) of mutations inKRAS. Next, we assessed risk of death when combiningKRASmutational status and tumor size. We found thatKRASMUTin combination with tumor size did not increase the risk of death.